Fig. 1

Cohort 1 (a) and Cohort 2 (b) patient distribution. a In cohort 1, 56 patients with newly diagnosed FLT3-mutated AML received induction therapy, and 32 and 8 patients with relapsed/refractory disease received a second or third FLT3i-based therapy, respectively. Overall, 40 subsequent FLT3i exposure events were identified in cohort 1. In cohort 2, 183 patients with relapsed/refractory FLT3-mutated AML received a FLT3-inhibitor based salvage therapy, and 89, 25, and 4 patients with relapsed/refractory disease received a second, third, or fourth FLT3i-based therapy, respectively. A total of 118 subsequent FLT3i exposure events were identified in cohort 2